ITCI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ITCI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-05-24), Intra-Cellular Therapies's current share price is $65.54. Intra-Cellular Therapies's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $1.59. Intra-Cellular Therapies's Cyclically Adjusted PS Ratio for today is 41.22.
The historical rank and industry rank for Intra-Cellular Therapies's Cyclically Adjusted PS Ratio or its related term are showing as below:
During the past years, Intra-Cellular Therapies's highest Cyclically Adjusted PS Ratio was 98.33. The lowest was 40.86. And the median was 63.34.
ITCI's Cyclically Adjusted PS Ratio is ranked worse thanThe Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Intra-Cellular Therapies's adjusted revenue per share data for the three months ended in Mar. 2024 was $1.495. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $1.59 for the trailing ten years ended in Mar. 2024.
The historical data trend for Intra-Cellular Therapies's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intra-Cellular Therapies Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cyclically Adjusted PS Ratio | Get a 7-Day Free Trial | 66.61 | 65.87 | 44.99 | 53.09 | 43.41 |
For the Drug Manufacturers - Specialty & Generic subindustry, Intra-Cellular Therapies's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Intra-Cellular Therapies's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Intra-Cellular Therapies's Cyclically Adjusted PS Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Intra-Cellular Therapies's Cyclically Adjusted PS Ratio for today is calculated as
Cyclically Adjusted PS Ratio | = | Share Price | / | Cyclically Adjusted Revenue per Share |
= | 65.54 | / | 1.59 | |
= | 41.22 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intra-Cellular Therapies's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:
For example, Intra-Cellular Therapies's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:
Adj_RevenuePerShare | = | Revenue per Share | / | CPI of Mar. 2024 (Change) | * | Current CPI (Mar. 2024) |
= | 1.495 | / | 131.7762 | * | 131.7762 | |
= | 1.495 |
Current CPI (Mar. 2024) = 131.7762.
Intra-Cellular Therapies Quarterly Data
Revenue per Share | CPI | Adj_RevenuePerShare | |
201406 | 0.007 | 100.560 | 0.009 |
201409 | 0.004 | 100.428 | 0.005 |
201412 | 0.001 | 99.070 | 0.001 |
201503 | 0.000 | 99.621 | 0.000 |
201506 | 0.002 | 100.684 | 0.003 |
201509 | 0.000 | 100.392 | 0.000 |
201512 | -0.001 | 99.792 | -0.001 |
201603 | 0.000 | 100.470 | 0.000 |
201606 | 0.005 | 101.688 | 0.006 |
201609 | 0.000 | 101.861 | 0.000 |
201612 | 0.002 | 101.863 | 0.003 |
201703 | 0.002 | 102.862 | 0.003 |
201706 | 0.003 | 103.349 | 0.004 |
201709 | 0.001 | 104.136 | 0.001 |
201712 | 0.000 | 104.011 | 0.000 |
201803 | 0.000 | 105.290 | 0.000 |
201806 | 0.000 | 106.317 | 0.000 |
201809 | 0.000 | 106.507 | 0.000 |
201812 | 0.000 | 105.998 | 0.000 |
201903 | 0.000 | 107.251 | 0.000 |
201906 | 0.000 | 108.070 | 0.000 |
201909 | 0.000 | 108.329 | 0.000 |
201912 | 0.000 | 108.420 | 0.000 |
202003 | 0.014 | 108.902 | 0.017 |
202006 | 0.028 | 108.767 | 0.034 |
202009 | 0.106 | 109.815 | 0.127 |
202012 | 0.154 | 109.897 | 0.185 |
202103 | 0.192 | 111.754 | 0.226 |
202106 | 0.234 | 114.631 | 0.269 |
202109 | 0.266 | 115.734 | 0.303 |
202112 | 0.313 | 117.630 | 0.351 |
202203 | 0.375 | 121.301 | 0.407 |
202206 | 0.584 | 125.017 | 0.616 |
202209 | 0.760 | 125.227 | 0.800 |
202212 | 0.923 | 125.222 | 0.971 |
202303 | 0.996 | 127.348 | 1.031 |
202306 | 1.148 | 128.729 | 1.175 |
202309 | 1.309 | 129.860 | 1.328 |
202312 | 1.366 | 129.419 | 1.391 |
202403 | 1.495 | 131.776 | 1.495 |
Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Thank you for viewing the detailed overview of Intra-Cellular Therapies's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Sharon Mates | director, officer: Chairman, President & CEO | C/O INTRA-CELLULAR THERAPIES, INC., 3960 BROADWAY, NEW YORK NY 10032 |
Michael Halstead | officer: SVP and General Counsel | C/O WARNER CHILCOTT CORPORATION, 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07866 |
Suresh K. Durgam | officer: Chief Medical Officer | C/O INTER-CELLULAR THERAPIES, INC., 430 EAST 29TH STREET, NEW YORK NY 10016 |
Mark Neumann | officer: EVP, Chief Commercial Officer | C/O INTRA-CELLULAR THERAPIES, INC., 430 EAST 29TH STREET, NEW YORK NY 10016 |
Lawrence J. Hineline | officer: VP of Finance, CFO & Secretary | C/O INTRA-CELLULAR THERAPIES, INC., 3960 BROADWAY, NEW YORK NY 10032 |
Van Nostrand Robert L | director | C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511 |
Joel S Marcus | director | C/O ALEXANDRIA REAL ESTATE EQUITIES, INC, 26 NORTH EUCLID AVENUE, PASADENA CA 91101 |
Eduardo Rene Salas | director | C/O INTRA-CELLULAR THERAPIES, INC., 430 EAST 29TH STREET, NEW YORK NY 10016 |
Rory B Riggs | director | 65 RAILROAD AVE, RIDGEFIELD NJ 07657 |
Christopher D Alafi | director, 10 percent owner | P.O. BOX 7338, BERKELEY CA 94707 |
Richard A Lerner | director | THE SCRIPPS RESEARCH INSTITUTE, 10550 N. TORREY PINES ROAD, LA JOLLA CA 92037 |
Andrew Satlin | officer: EVP and Chief Medical Officer | C/O INTRA-CELLULAR THERAPIES, INC., 430 EAST 29TH STREET, NEW YORK NY 10016 |
Kimberly E. Vanover | officer: VP, Clinical Development | C/O INTRA-CELLULAR THERAPIES, INC., 3960 BROADWAY, NEW YORK NY 10032 |
Robert E Davis | officer: SVP, Chief Scientific Officer | 3911 SORRENTO VALLEY BOULEVARD, SAN DIEGO CA 92121 |
Moshe Alafi | 10 percent owner | 1311 ORLEANS DRIVE, SUNNYVALE CA 94089 |
From GuruFocus
By Value_Insider Value_Insider • 12-08-2022
By GuruFocus Research • 12-25-2023
By GuruFocus Research • 01-05-2024
By Value_Insider Value_Insider • 11-10-2022
By sperokesalga sperokesalga • 06-05-2023
By Marketwired • 10-26-2023
By GuruFocus Research • 11-02-2023
By sperokesalga sperokesalga • 05-31-2023
By GuruFocus Research • 12-16-2023
By GuruFocus Research • 01-13-2024